Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Neurocrine Biosciences Q2 revenue rises 39%, boosts 2026 sales forecast after Soleno acquisition
NBIX
$166.57
-$18.93 -10.20%

Neurocrine Biosciences Q2 revenue rises 39%, boosts 2026 sales forecast after Soleno acquisition

Company Fundamentals
30 Jul 2026
PRNewsWire
View Source
Bullish
pluang ai news

Neurocrine Biosciences reported a 39% year-over-year revenue increase to $959 million in Q2 2026, driven by strong sales of INGREZZA, CRENESSITY, and new product VYKAT XR following its acquisition of Soleno Therapeutics. The company raised its full-year 2026 sales guidance for INGREZZA to $2.825-$2.875 billion, reflecting robust patient demand and expanded commercial efforts. Key clinical milestones are expected in 2027, including Phase 3 trial results for treatments targeting major depressive disorder and schizophrenia, positioning Neurocrine for sustained growth and innovation.

More News (NBIX)

Neurocrine Biosciences posts strong Q2 revenue growth and raises 2026 sales guidance.

Neurocrine Biosciences posts strong Q2 revenue growth and raises 2026 sales guidance.

Neurocrine Biosciences reported a 39% increase in Q2 2026 revenues to $959 million and non-GAAP earnings of $2.85 per share, beating estimates. Sales of its key drug INGREZZA rose 15% year-over-year, prompting the company to raise its 2026 sales fore...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App